| Patent application number | Description | Published |
|---|
| 20090093055 | Islet Cells from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 04-09-2009 |
| 20090325180 | Drug Screening using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 12-31-2009 |
| 20100196916 | Drug Screening using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 08-05-2010 |
| 20110065118 | Drug Screening Using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 03-17-2011 |
| Patent application number | Description | Published |
|---|
| 20090047243 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS - The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma. | 02-19-2009 |
| 20090053168 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS - The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound. | 02-26-2009 |
| 20100009934 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS - The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder. | 01-14-2010 |
